Beacon Therapeutics Secures Over $75 Million in Series C Financing
On January 8, 2026, Beacon Therapeutics Holdings Limited, a leading clinical-stage biotechnology company based in London and Cambridge, announced the successful closure of an oversubscribed Series C financing round, raising over $75 million. This significant funding event was primarily led by the Life Sciences division at Goldman Sachs Alternatives (NYSE: GS), complemented by participation from the Retinal Degeneration Fund, along with existing investors including Syncona Limited, Forbion, Oxford Science Enterprises, and Advent Life Sciences.
Funds to Propel Vision Restoration Innovations
The funds raised will be instrumental in advancing Beacon’s lead program, laru-zova, toward commercialization, particularly for the treatment of X-linked retinitis pigmentosa (XLRP). Additionally, this financing will accelerate the development of other promising candidates in Beacon’s pipeline.
Dr. Lance Baldo, CEO of Beacon Therapeutics, stated, “This significant fundraising validates our strategy to save and restore sight for people living with rare and prevalent ocular diseases. With pivotal laru-zova data expected in the second half of 2026, these funds will accelerate our commercial preparations for this potentially life-changing product.”
- $75 million+: Total raised in Series C financing.
- New investors include Life Sciences at Goldman Sachs Alternatives and Retinal Degeneration Fund.
- Existing investors: Syncona Limited, Forbion, Oxford Science Enterprises, Advent Life Sciences.
Strengthening Leadership and Strategic Engagements
In conjunction with this financing, Beacon Therapeutics appointed Colin Walsh, PhD, Managing Director at Life Sciences at Goldman Sachs Alternatives, to its Board of Directors. Walsh expressed enthusiasm about collaborating with Beacon Therapeutics, recognizing its potential in ocular gene therapy and the advancement of laru-zova through clinical trials.
Walsh highlighted, “With laru-zova's advancement through pivotal trials, the Company is setting the roadmap for how to build successful gene therapies and bring transformative treatments to patients with XLRP.”
Implications for Patients with X-linked Retinitis Pigmentosa
Retinitis pigmentosa (RP) impacts over 100,000 patients in the United States, with approximately 14% having XLRP, a condition currently without available treatment options. The successful development of laru-zova has the potential to halt disease progression and significantly improve the quality of life for affected individuals.
Dr. Rusty Kelley, Managing Director of the RD Fund, remarked, “We are proud to support Beacon as it approaches the pivotal VISTA trial readout of laru-zova later this year.”
Upcoming Presentation at JP Morgan Healthcare Conference
Beacon Therapeutics will present at the 44th Annual JP Morgan Healthcare Conference from January 12-15, 2026, in San Francisco. The presentation is scheduled for January 13th at 2:30 PM PT.
About Beacon Therapeutics
Beacon Therapeutics is dedicated to saving and restoring sight for individuals suffering from severe ocular diseases, utilizing the transformative power of gene therapy. Its pipeline targets blinding retinal diseases, including XLRP and geographic atrophy.